Caged Ceramide-1-Phosphate Derivatives for Intracellular Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering ceramide-1-phosphate (C1P) intracellularly are inefficient and often induce artifacts, limiting research and therapeutic applications due to the use of vehicles like dodecane and the difficulty in transfecting certain cell types.
Innovation Solution
Development of D-erythro ceramide-1-phosphate derivatives with specific structural modifications, such as benzhydryl and coumarinyl-4-methyl derivatives, which can be photochemically uncaged to facilitate intracellular delivery without cytotoxic effects, allowing for targeted and efficient introduction of C1P into various cell types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If C1P is delivered using dodecane/ethanol or dodecane/methanol mixtures, then intracellular delivery is achieved, but artifacts are induced in cells making observed effects unreliable
Solution Approach 1:
The patent uses caged compounds as intermediary carriers that can be delivered to cells in a biocompatible form (aqueous solution) and then converted to active C1P inside the cell through photochemical uncaging. This mediator approach avoids direct introduction of toxic dodecane while achieving the same intracellular delivery goal.
Solution Approach 2:
The patent replaces the mechanical/chemical delivery system (dodecane-based vehicle) with a photochemical system. Instead of using solvents to force C1P into cells, the invention uses light-triggered chemical transformation of caged compounds that have already entered cells through normal membrane permeation, substituting a harmful mechanical delivery method with a cleaner photochemical activation method.
2Adaptability or versatility
If cells are transfected with ceramide kinase to produce C1P in situ, then intracellular C1P is generated, but many cell types cannot be transfected
Solution Approach 1:
The caged compound acts as a pre-packaged intermediary that contains both the C1P molecule and its protective cage in a single deliverable unit. This eliminates the need for transfection of ceramide kinase, as the active molecule is already synthesized and protected in the caged form, making it universally applicable to all cell types that can take up the compound.
Solution Approach 2:
The C1P molecule is preliminarily prepared and protected in caged form before delivery. The chemical structure is pre-modified with the caged group, and the compound is pre-synthesized in biocompatible form, so that when delivered to cells, it requires only photochemical activation rather than enzymatic synthesis through transfection.
3Object-affected harmful factors
If caged C1P compounds are used for intracellular delivery, then C1P can be introduced without cytotoxic vehicles, but the compounds require photochemical uncaging
Solution Approach 1:
The patent replaces harmful chemical delivery vehicles with a photochemical activation system. The caged compounds are delivered in biocompatible aqueous solutions, and the active C1P is released through light-triggered photochemical reactions rather than through toxic solvent extraction or enzymatic processing, eliminating cytotoxic effects while adding only a light activation step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The caged C1P compounds enable effective intracellular delivery of C1P, stimulating cell growth, promoting survival, and inhibiting apoptosis, with potential therapeutic applications in treating diseases associated with cell death, inflammation, and metabolic disorders.
Implementation Method 1
which can be photochemically uncaged to facilitate intracellular delivery without cytotoxic effects
Data Source
AI summary
The invention relates to novel caged ceramide 1-phosphate (C1P), caged ceramide 1-phosphate derivatives(C1P), and the method of using them for delivering C1P intracellularly in vitro and in vivo, for research and therapeutic purposes. Therapeutic purposes include treatment of diseases associated with cell death, such as neurodegerative diseases, including Alzheimer's disease. The disclosed compositions may also be used for wound healing.